Key Inclusion Criteria:

• Histologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative chemotherapy measures do not exist or are no longer effective.
• Age >18 years old.
• ECOG Performance Status < 2.
• Female patients may not be pregnant or lactating and must be willing to practice contraception.

• Adequate organ function as defined by the following:

  • Serum creatinine < 1.5 mg/dl
  • Absolute neutrophil count (ANC) > 1500/L
  • Platelets > 100,000/L
  • Total bilirubin < upper limit of normal (ULN) for the reference lab
  • AST, ALT, and alkaline phosphatase must be within the designated range allowing for eligibility.

Key Exclusion Criteria:

• Other chemotherapy treatment < 4 weeks prior to enrollment
• Treatment with capecitabine, 5-fluorouracil (5-FU), or a platinum agent < 3 months from time of enrollment
• Radiotherapy involving > 30% of the active bone marrow
• Radiotherapy < 4 weeks prior to enrollment
• Pre-existing peripheral neuropathy > grade 1
• Pre-existing hearing loss > grade 2
• Metastatic brain or meningeal tumors unless the patient is > 6 months from definitive therapy, had a negative imaging study within 4 weeks of study entry, is clinically stable with respect to the tumor at the time of study entry, and is not receiving steroid therapy or taper

• Patients who have not recovered (> grade 1) from the following toxicities of previous regimens before enrollment:

  • hematologic toxicities
  • fatigue
  • mucositis
  • nausea/vomiting
  • diarrhea
• Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation).
• Uncontrolled intercurrent illness including, but not limited to, ongoing active infection, uncontrolled congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness that would limit compliance with study requirements.
• History of hypersensitivity reaction to capecitabine, 5-FU or any platinum containing drugs.
• History of human immunodeficiency (HIV) or acquired immunodeficiency syndrome (AIDS) related illness.
• Evidence of concurrent second malignancy other than basal cell carcinoma of the skin or cervical carcinoma in situ
• Concurrent use of medications that inhibit cytochrome P450 3A4 (including aprepitant).
• History of bone marrow or major organ transplant.